ReviewFrontiers in public health2023
Intervertebral disc degeneration-Current therapeutic options and challenges.
Review in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed.
- Impact of 3-dimensional myofascial release on tumor necrosis factor (TNF) alpha biomarker in nonspecific low back pain: a randomised controlled trial.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Trial
- Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study.BMC musculoskeletal disorders · 2025Trial
- Ginsenoside Rh2 Attenuates Intervertebral Disc Degeneration by Modulating the PI3K/AKT Signaling Pathway to Suppress Apoptosis.International journal of molecular sciences · 2026Article
- Elucidation of Baicalein's Anti-Intervertebral Disc Degeneration Mechanism Through Network Pharmacology and Experimental Validation.Cell biochemistry and biophysics · 2026Article
- Biomaterial-based strategies targeting ferroptosis for alleviating intervertebral disc degeneration: Advances and perspectives.Journal of orthopaedic translation · 2026Review
- Conservative Management of a Symptomatic Anterior Limbus Vertebra in a Non-athletic Patient: A Case Report.Cureus · 2026Article
- Integrated Multi-Omics Analysis and Experimental Validation Identify UBE2Q2 as a Candidate Molecule Target in Intervertebral Disc Degeneration.Journal of cellular and molecular medicine · 2026Article
- Epigenetic research methods and animal models for intervertebral disc degeneration (Review).Molecular medicine reports · 2026Review
- Mitigating nucleus pulposus cell senescence in intervertebral disk degeneration: the role of nodakenin in SIRT6 and PINK1/Parkin-associated mitophagy signaling.Cellular & molecular biology letters · 2026Article
- Wogonin Ameliorates the Oxidative Stress, Apoptosis, and Extracellular Matrix Degradation of Nucleus Pulposus Cells Mediated byInternational journal of molecular sciences · 2026Article
- From undruggable to degradable: A deep learning-enabled framework for precision orthopaedic protein degradation.Journal of orthopaedic translation · 2026Review
- Integrated Molecular Docking and Network-Based Analysis Reveals Multitarget Interaction Patterns of Nutraceutical Compounds in Intervertebral Disc Degeneration.Biomedicines · 2026Article
- From collapse to comeback: Luteolin rejuvenates nucleus pulposus progenitor cells via SIRT1/ATF5-UPRmt to reverse intervertebral disc degeneration cascade.Stem cell research & therapy · 2026Article
- Exosomes derived from senescent skeletal muscle cells aggravate nucleus pulposus cell metabolic dysregulation via p38MAPK pathway for promoting intervertebral disc degeneration.BMC musculoskeletal disorders · 2026Article
- Epigenetic crossroads in intervertebral disc degeneration: Unlocking novel therapeutic avenues (Review).Molecular medicine reports · 2026Review
- Multi-omics Mendelian randomization prioritizes BMP6 as a candidate therapeutic target in intervertebral disc degeneration.Journal of orthopaedic surgery and research · 2026Article
- The protective up-regulation of metallothionein-2A in intervertebral disc degeneration inhibits nucleus pulposus cell ferroptosis through activation of the PI3K/AKT/mTOR pathway.Cell death discovery · 2026Article
- Aberrantly expressed long noncoding RNAs in adipose-derived mesenchymal stem cells differentiation to nucleus pulposus-like cells.Scientific reports · 2026Article
- Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026Review
- One-Stone-Three-Birds Biomimetic Oral Targeting Delivery Strategy for On-Demand Controlled Drug Release and Intervertebral Disc Degeneration Therapy.Exploration (Beijing, China) · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Degeneration of the intervertebral disc (IVD) is a normal part of aging. Due to the spine's declining function and the development of pain, it may affect one's physical health, mental health, and socioeconomic status. Most of the intervertebral disc degeneration (IVDD) therapies today focus on the symptoms of low back pain rather than the underlying etiology or mechanical function of the disc. The deteriorated disc is typically not restored by conservative or surgical therapies that largely focus on correcting symptoms and structural abnormalities. To enhance the clinical outcome and the quality of life of a patient, several therapeutic modalities have been created. In this review, we discuss genetic and environmental causes of IVDD and describe promising modern endogenous and exogenous therapeutic approaches including their applicability and relevance to the degeneration process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.